JP2010512779A5 - - Google Patents

Download PDF

Info

Publication number
JP2010512779A5
JP2010512779A5 JP2009542273A JP2009542273A JP2010512779A5 JP 2010512779 A5 JP2010512779 A5 JP 2010512779A5 JP 2009542273 A JP2009542273 A JP 2009542273A JP 2009542273 A JP2009542273 A JP 2009542273A JP 2010512779 A5 JP2010512779 A5 JP 2010512779A5
Authority
JP
Japan
Prior art keywords
recombinant
strand rna
segmented
rna virus
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009542273A
Other languages
English (en)
Japanese (ja)
Other versions
JP5902371B2 (ja
JP2010512779A (ja
Filing date
Publication date
Priority claimed from EP06292025.1A external-priority patent/EP1939214B1/en
Application filed filed Critical
Publication of JP2010512779A publication Critical patent/JP2010512779A/ja
Publication of JP2010512779A5 publication Critical patent/JP2010512779A5/ja
Application granted granted Critical
Publication of JP5902371B2 publication Critical patent/JP5902371B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009542273A 2006-12-22 2007-12-21 非分節型マイナス鎖rnaウイルスを作出するための細胞及び方法 Active JP5902371B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06292025.1 2006-12-22
EP06292025.1A EP1939214B1 (en) 2006-12-22 2006-12-22 Cells and methodology to generate non-segmented negative-strand RNA viruses
PCT/IB2007/004444 WO2008078198A2 (en) 2006-12-22 2007-12-21 Cells and methodology to generate non-segmented negative-strand rna viruses

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014169418A Division JP2015015955A (ja) 2006-12-22 2014-08-22 非分節型マイナス鎖rnaウイルスを作出するための細胞及び方法

Publications (3)

Publication Number Publication Date
JP2010512779A JP2010512779A (ja) 2010-04-30
JP2010512779A5 true JP2010512779A5 (enExample) 2014-10-16
JP5902371B2 JP5902371B2 (ja) 2016-04-13

Family

ID=37831098

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2009542273A Active JP5902371B2 (ja) 2006-12-22 2007-12-21 非分節型マイナス鎖rnaウイルスを作出するための細胞及び方法
JP2014169418A Pending JP2015015955A (ja) 2006-12-22 2014-08-22 非分節型マイナス鎖rnaウイルスを作出するための細胞及び方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014169418A Pending JP2015015955A (ja) 2006-12-22 2014-08-22 非分節型マイナス鎖rnaウイルスを作出するための細胞及び方法

Country Status (11)

Country Link
US (2) US8586364B2 (enExample)
EP (2) EP1939214B1 (enExample)
JP (2) JP5902371B2 (enExample)
KR (1) KR101469007B1 (enExample)
CN (2) CN104745533A (enExample)
BR (1) BRPI0719469C1 (enExample)
CA (1) CA2673262C (enExample)
DK (2) DK1939214T3 (enExample)
ES (2) ES2423518T3 (enExample)
MX (1) MX2009006755A (enExample)
WO (1) WO2008078198A2 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2110382A1 (en) 2002-06-20 2009-10-21 Institut Pasteur Infectious cDNA of an improved vaccine strain of measles virus, use for immunogenic compositions
DK1375670T3 (da) 2002-06-20 2013-09-23 Pasteur Institut Rekombinante mæslingevira, der udtrykker epitoper af RNA-viras antigener, samt anvendelse af de rekombinante vira til fremstilling af vaccinesammensætninger
CA2432738A1 (en) 2003-02-26 2004-08-26 Philippe Despres New dengue and west nile viruses proteins and genes coding the foregoing, and their use in vaccinal, therapeutic and diagnostic applications
WO2012038832A2 (en) * 2010-09-24 2012-03-29 Institut Pasteur Generation of replicating chimeric measles virus - retrovirus particles
CN103906843B (zh) * 2011-06-08 2016-12-07 维什瓦斯·乔希 双质粒哺乳动物表达系统
FR2994697B1 (fr) * 2012-08-24 2016-05-13 Centre De Coop Int En Rech Agronomique Pour Le Dev (Cirad) Souche vaccinale marquee du virus de la peste des petits ruminants, et son procede d'obtention
EP2712871A1 (en) 2012-09-27 2014-04-02 Institut Pasteur Recombinant Measles virus expressing Chikungunya virus polypeptides and their applications
EP2759301A1 (en) 2013-01-24 2014-07-30 Institut Pasteur Use of a genetically modified infectious measles virus with enhanced pro-apoptotic properties (MV-DeltaC virus)
US20140255447A1 (en) * 2013-03-05 2014-09-11 Biomune Company Production of avian embryo cells
WO2015092710A1 (en) 2013-12-19 2015-06-25 Glaxosmithkline Biologicals, S.A. Contralateral co-administration of vaccines
GB2550522B (en) 2015-01-05 2020-12-16 Seagull Biosolutions Pvt Ltd DNA molecules producing custom designed replicating and non-replicating negative stranded RNA viruses and uses there of
EP3184119A1 (en) 2015-12-23 2017-06-28 Themis Bioscience GmbH Chromatography based purification strategies for measles scaffold based viruses
EP3255056A1 (en) * 2016-06-06 2017-12-13 Commissariat À L'Énergie Atomique Et Aux Énergies Alternatives Method for producing self-assemblying paramyxoviral nucleocapsid-like particles and their uses
WO2018206512A1 (en) 2017-05-09 2018-11-15 Invectys Recombinant measles vaccine expressing htert
EP3412307A1 (en) 2017-06-07 2018-12-12 Institut Pasteur Recombinant measles virus expressing zika virus proteins and their applications
CN107557340A (zh) * 2017-09-26 2018-01-09 南京普菲科医药科技有限公司 一种可诱导性拯救弹状病毒的细胞系及其构建方法与应用
SG11202004234SA (en) 2017-11-09 2020-06-29 Pasteur Institut A zika virus chimeric polyepitope comprising non-structural proteins and its use in an immunogenic composition
SG11202004899SA (en) 2017-12-21 2020-06-29 Pasteur Institut Lassa vaccine
CA3106286A1 (en) 2018-07-13 2020-01-16 Valneva Se Method for rescuing and producing a virus in avian cells
CN109355301A (zh) * 2018-08-22 2019-02-19 深圳大学 一种石斑鱼重组NNVcp的密码子优化的核酸序列、融合表达载体、制备方法及其本身
CN111218474A (zh) * 2018-11-23 2020-06-02 成都生物制品研究所有限责任公司 一种副粘病毒的拯救系统和副粘病毒拯救方法
EP3673917A1 (en) 2018-12-28 2020-07-01 Themis Bioscience GmbH Norovirus vaccines
CN109913423A (zh) * 2019-03-27 2019-06-21 扬州大学 一种稳定表达猪德尔塔冠状病毒N蛋白的重组Vero细胞系及应用
WO2021160850A1 (en) 2020-02-13 2021-08-19 Institut Pasteur Measles-vectored covid-19 immunogenic compositions and vaccines
EP3865180A1 (en) 2020-02-13 2021-08-18 Institut Pasteur Live recombinant measles virus expressing coronavirus antigens - its use in eliciting immunity against coronaviruses
EP4142786A4 (en) * 2020-04-27 2024-06-19 Ohio State Innovation Foundation LIVE ATTENUATED MEASLES VIRUS VACCINE AGAINST SARS-COV-2
EP3936517A1 (en) * 2020-07-08 2022-01-12 Institut Pasteur An improved measles virus vaccine vector based on multiple tandem additional transcription units
EP4277704A1 (en) 2021-01-13 2023-11-22 Viroxis Measles-hiv or measles-htlv vaccine
WO2023230598A2 (en) * 2022-05-27 2023-11-30 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Reverse genetics system for feline morbillivirus
EP4501946A1 (en) 2023-07-31 2025-02-05 LoopLab Bio GmbH Self-amplifying biologics for targeted therapy
WO2026013289A1 (en) 2024-07-12 2026-01-15 Institut Pasteur Measles-mumps-rubella (mmr) vaccines
CN120648655B (zh) * 2025-08-21 2026-02-13 内蒙古自治区农牧业科学院 一株t7-293t细胞及其在牛副流感病毒3型感染性克隆拯救病毒中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE181112T1 (de) * 1995-08-09 1999-06-15 Schweiz Serum & Impfinst Dem genom von minussträngigen rna-viren entsprechende cdna und verfahren zur herstellung von infektiösen minussträngigen rna-viren
WO2001027304A2 (en) 1999-10-12 2001-04-19 Institut Pasteur Lentiviral triplex dna, and vectors and recombinant cells containing lentiviral triplex dna
CA2412257A1 (en) 2000-06-16 2001-12-20 Institut Pasteur Pro-apoptotic fragments of the dengue virus envelope glycoproteins
DK1375670T3 (da) 2002-06-20 2013-09-23 Pasteur Institut Rekombinante mæslingevira, der udtrykker epitoper af RNA-viras antigener, samt anvendelse af de rekombinante vira til fremstilling af vaccinesammensætninger
DE10234579A1 (de) * 2002-07-30 2004-02-12 Zf Friedrichshafen Ag Getriebe
WO2004113517A2 (en) * 2003-06-09 2004-12-29 Wyeth IMPROVED METHOD FOR THE RECOVERY OF NON-SEGMENTED, NEGATIVE-STRANDED RNA VIRUSES FROM cDNA
JP5090741B2 (ja) 2003-12-02 2012-12-05 インスティティ・パスツール 新規なsars関連コロナウイルス系統のゲノムによりコードされるタンパク質及びペプチドの利用
FR2870126B1 (fr) 2004-05-17 2009-07-17 Pasteur Institut Vecteur lentiviral recombinant d'expression d'une proteine de flaviviridae et ses applications comme vaccin
EP1874348A4 (en) * 2005-04-14 2009-10-28 Univ Queensland IMMUNOREGULATORY COMPOSITIONS AND THEIR USE

Similar Documents

Publication Publication Date Title
Cowan et al. Enhancing the functional properties of thermophilic enzymes by chemical modification and immobilization
JP2011062217A5 (enExample)
JP2015119730A5 (enExample)
JP2022503959A5 (enExample)
NZ590144A (en) Influenza virus-like particles (vlps) comprising hemagglutinin
WO2007002008A3 (en) Methods and compositions for expressing negative-sense viral rna in canine cells
JP2010227108A5 (enExample)
JP2018520654A5 (enExample)
WO2007124327A3 (en) Methods and compositions for expressing negative-sense viral rna in canine cells
JP2012095652A5 (enExample)
JP2010279377A5 (enExample)
WO2010040526A8 (de) Lcmv-gp-vsv-pseudotypvektoren und tumorinfiltrierende virenproduzentenzellen zur therapie von tumoren
JP2011525793A5 (enExample)
WO2007048089A3 (en) Multi-plasmid system for the production of influenza virus
BRPI0719469C1 (pt) vetores de expressão derivados de retrovírus e métodos para produzir um vírus infeccioso de sarampo
PH12013502600A1 (en) Rabies virus like particle production in plants
WO2013049121A3 (en) Recombinant phage and methods
WO2008129971A1 (ja) 改良された持続感染型センダイウイルスベクター
Pejman et al. Gradient-based hybrid topology/shape optimization of bioinspired microvascular composites
MX2018006627A (es) Aumentar el rendimiento de particulas similares a virus en plantas.
Kranzusch et al. Architecture and regulation of negative-strand viral enzymatic machinery
WO2009099877A3 (en) Closterovirus vectors and methods
JP2021520815A5 (enExample)
EA201400192A1 (ru) Клетка, ферментирующая пентозы
CL2008003821A1 (es) Metodo para producir el virus de la estomatitis vesicular (vsv) atenuado en celulas, que comprende: a) proporcionar una celula que comprende un gen g vsv optimizado e inducible, b) inducir la celula a expresar dicho gen, c) infectar la celula con un vsv atenuado, d) hacer crecer dichas celulas, y e) recuperar el vsv atenuado